Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 1/2014

Open Access 01-01-2014 | Review

Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives

Authors: Marta Sobczak, Maciej Sałaga, Martin A. Storr, Jakub Fichna

Published in: Journal of Gastroenterology | Issue 1/2014

Login to get access

Abstract

Opioid receptors are widely distributed in the human body and are crucially involved in numerous physiological processes. These include pain signaling in the central and the peripheral nervous system, reproduction, growth, respiration, and immunological response. Opioid receptors additionally play a major role in the gastrointestinal (GI) tract in physiological and pathophysiological conditions. This review discusses the physiology and pharmacology of the opioid system in the GI tract. We additionally focus on GI disorders and malfunctions, where pathophysiology involves the endogenous opioid system, such as opioid-induced bowel dysfunction, opioid-induced constipation or abdominal pain. Based on recent reports in the field of pharmacology and medicinal chemistry, we will also discuss the opportunities of targeting the opioid system, suggesting future treatment options for functional disorders and inflammatory states of the GI tract.
Literature
1.
Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973;179:1011–4.PubMed
2.
Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977;267:495–9.PubMed
3.
Dupre DJ, Robitaille M, Rebois RV, Hebert TE. The role of Gbetagamma subunits in the organization, assembly, and function of GPCR signaling complexes. Annu Rev Pharmacol Toxicol. 2009;49:31–56.PubMedPubMedCentral
4.
Piros ET, Hales TG, Evans CJ. Functional analysis of cloned opioid receptors in transfected cell lines. Neurochem Res. 1996;21:1277–85.PubMed
5.
Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science. 1992;258:1952–5.PubMed
6.
Li S, Zhu J, Chen C, Chen YW, Deriel JK, Ashby B, et al. Molecular cloning and expression of a rat kappa opioid receptor. Biochem J. 1993;295:629–33.PubMed
7.
Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J. 1993;295:625–8.PubMed
8.
Fukuda K, Kato S, Mori K, Nishi M, Takeshima H. Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. FEBS Lett. 1993;327:311–4.PubMed
9.
Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? Br J Anaesth. 2011;107:8–18.PubMed
10.
Zollner C, Stein C. Opioids. Handb Exp Pharmacol. 2007;177:31–63.PubMed
11.
Jordan BA, Cvejic S, Devi LA. Opioids and their complicated receptor complexes. Neuropsychopharmacology. 2000;23:S5–18.PubMed
12.
Chaturvedi K, Christoffers KH, Singh K, Howells RD. Structure and regulation of opioid receptors. Biopolymers. 2000;55:334–46.PubMed
13.
Befort K, Tabbara L, Bausch S, Chavkin C, Evans C, Kieffer B. The conserved aspartate residue in the third putative transmembrane domain of the delta-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol Pharmacol. 1996;49:216–23.PubMed
14.
Surratt CK, Johnson PS, Moriwaki A, Seidleck BK, Blaschak CJ, Wang JB, et al. mu opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J Biol Chem. 1994;269:20548–53.PubMed
15.
Chan AS, Law PY, Loh HH, Ho PN, Wu WM, Chan JS, et al. The first and third intracellular loops together with the carboxy terminal tail of the delta-opioid receptor contribute toward functional interaction with Galpha16. J Neurochem. 2003;87:697–708.PubMed
16.
Reisine T, Law SF, Blake A, Tallent M. Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann N Y Acad Sci. 1996;780:168–75.PubMed
17.
Clark MJ, Neubig RR, Traynor JR. Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization. J Pharmacol Exp Ther. 2004;310:215–22.PubMed
18.
Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol. 2000;40:389–430.PubMed
19.
Piros ET, Prather PL, Law PY, Evans CJ, Hales TG. Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors. Mol Pharmacol. 1996;50:947–56.PubMed
20.
Georgoussi Z, Georganta EM, Milligan G. The other side of opioid receptor signalling: regulation by protein–protein interaction. Curr Drug Targets. 2012;13:80–102.PubMed
21.
Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308:512–7.PubMed
22.
Maguma H, Thayne K, Taylor DA. Characteristics of tolerance in the guinea pig ileum produced by chronic in vivo exposure to opioid versus cannabinoid agonists. Biochem Pharmacol. 2010;80:522–32.PubMed
23.
Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature. 2000;408:720–3.PubMed
24.
Fernandez Robles CR, Degnan M, Candiotti KA. Pain and genetics. Curr Opin Anaesthesiol. 2012;25:444–9.
25.
Levran O, Yuferov V, Kreek MJ. The genetics of the opioid system and specific drug addictions. Hum Genet. 2012;131:823–42.PubMedPubMedCentral
26.
Raynor K, Kong H, Mestek A, Bye LS, Tian M, Liu J, et al. Characterization of the cloned human mu opioid receptor. J Pharmacol Exp Ther. 1995;272:423–8.PubMed
27.
Chadzinska M. Opioid system and innate immunity. Comparative studies. I. Opioids and opioid receptors. Adv Cell Biol. 2007;34:251–62.
28.
Cruz-Gordillo P, Fedrigo O, Wray GA, Babbitt CC. Extensive changes in the expression of the opioid genes between humans and chimpanzees. Brain Behav Evol. 2010;76:154–62.PubMed
29.
Sehgal N, Smith HS, Manchikanti L. Peripherally acting opioids and clinical implications for pain control. Pain Physician. 2011;14:249–58.PubMed
30.
Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, et al. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet. 2006;15:807–19.PubMedPubMedCentral
31.
Finco G, Pintor M, Sanna D, Orru G, Musu M, De CF, et al. Is target opioid therapy within sight? Minerva Anestesiol. 2012;78:462–72.PubMed
32.
Kosarac B, Fox AA, Collard CD. Effect of genetic factors on opioid action. Curr Opin Anaesthesiol. 2009;22:476–82.PubMed
33.
Chavkin C, McLaughlin JP, Celver JP. Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol. 2001;60:20–5.PubMed
34.
Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A>G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48:1232–9.PubMed
35.
Walter C, Lotsch J. Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain. 2009;146:270–5.PubMed
36.
Ashenhurst JR, Bujarski S, Ray LA. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav. 2012;103:253–9.PubMedPubMedCentral
37.
Crist RC, Ambrose-Lanci LM, Vaswani M, Clarke TK, Zeng A, Yuan C, et al. Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations. Drug Alcohol Depend. 2013;127:122–8.PubMedPubMedCentral
38.
Arias AJ, Armeli S, Gelernter J, Covault J, Kallio A, Karhuvaara S, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008;32:1159–66.PubMedPubMedCentral
39.
Zhang H, Gelernter J, Gruen JR, Kranzler HR, Herman AI, Simen AA. Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. J Hum Genet. 2010;55:278–84.PubMedPubMedCentral
40.
41.
Edenberg HJ, Wang J, Tian H, Pochareddy S, Xuei X, Wetherill L, et al. A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence. Hum Mol Genet. 2008;17:1783–9.PubMed
42.
Peng J, Sarkar S, Chang SL. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol Depend. 2012;124:223–8.PubMedPubMedCentral
43.
Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol. 2010;23:616–22.PubMed
44.
Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004;16(Suppl 2):17–28.PubMed
45.
Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil. 2004;16(Suppl 2):3–16.PubMed
46.
DeHaven-Hudkins DL, DeHaven RN, Little PJ, Techner LM. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor. Pharmacol Ther. 2008;117:162–87.
47.
Poole DP, Pelayo JC, Scherrer G, Evans CJ, Kieffer BL, Bunnett NW. Localization and regulation of fluorescently labeled delta opioid receptor, expressed in enteric neurons of mice. Gastroenterology. 2011;141:982–91.PubMed
48.
Phan NQ, Lotts T, Antal A, Bernhard JD, Stander S. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review. Acta Derm Venereol. 2012;92:555–60.PubMed
49.
Bagnol D, Mansour A, Akil H, Watson SJ. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997;81:579–91.PubMed
50.
Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–71.PubMed
51.
Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361:192–5.PubMed
52.
Donnerer J, Liebmann I. Stimulus-evoked opioid inhibition in guinea-pig longitudinal muscle-myenteric plexus strip is modulated by NMDA receptors. Neurosci Lett. 2007;419:74–7.PubMed
53.
Patierno S, Zellalem W, Ho A, Parsons CG, Lloyd KC, Tonini M, et al. N-methyl-D-aspartate receptors mediate endogenous opioid release in enteric neurons after abdominal surgery. Gastroenterology. 2005;128:2009–19.PubMed
54.
Donnerer J, Liebmann I. Evidence for opioid-induced release of glutamate in guinea pig longitudinal muscle-myenteric plexus strip. Neurosci Lett. 2009;462:118–20.PubMed
55.
Iwata H, Tsuchiya S, Nakamura T, Yano S. Morphine leads to contraction of the ileal circular muscle via inhibition of the nitrergic pathway in mice. Eur J Pharmacol. 2007;574:66–70.PubMed
56.
De LA, Coupar IM. Insights into opioid action in the intestinal tract. Pharmacol Ther. 1996;69(2):103–15.
57.
Brock C, Olesen SS, Olesen AE, Frokjaer JB, Andresen T, Drewes AM. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847–65.PubMed
58.
Barrett KE. New insights into the pathogenesis of intestinal dysfunction: secretory diarrhea and cystic fibrosis. World J Gastroenterol. 2000;6:470–4.PubMed
59.
Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol. 2000;62:535–72.PubMed
60.
Herman MA, Gillis RA, Vicini S, Dretchen KL, Sahibzada N. Tonic GABAA receptor conductance in medial subnucleus of the tractus solitarius neurons is inhibited by activation of mu-opioid receptors. J Neurophysiol. 2012;107:1022–31.PubMed
61.
Herman MA, Alayan A, Sahibzada N, Bayer B, Verbalis J, Dretchen KL, et al. micro-Opioid receptor stimulation in the medial subnucleus of the tractus solitarius inhibits gastric tone and motility by reducing local GABA activity. Am J Physiol Gastrointest Liver Physiol. 2010;299:G494–506.PubMed
62.
Vilardaga JP, Bunemann M, Feinstein TN, Lambert N, Nikolaev VO, Engelhardt S, et al. GPCR and G proteins: drug efficacy and activation in live cells. Mol Endocrinol. 2009;23:590–9.PubMed
63.
Gomez MP, Nasi E. Light transduction in invertebrate hyperpolarizing photoreceptors: possible involvement of a Go-regulated guanylate cyclase. J Neurosci. 2000;20:5254–63.PubMed
64.
Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, et al. Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem. 2000;280:11152–64.
65.
Berger AC, Whistler JL. Morphine-induced mu opioid receptor trafficking enhances reward yet prevents compulsive drug use. EMBO Mol Med. 2011;3:385–97.PubMedPubMedCentral
66.
Milligan G. G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta. 2007;1768:825–35.PubMed
67.
Milligan G, Parenty G, Stoddart LA, Lane JR. Novel pharmacological applications of G-protein-coupled receptor-G protein fusions. Curr Opin Pharmacol. 2007;7:521–6.PubMed
68.
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115:1363–81.PubMedPubMedCentral
69.
Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol. 2006;148:387–95.PubMed
70.
71.
Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis. 2012;16:331–46.PubMed
72.
Headrick JP, Pepe S, Peart JN. Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems. Curr Pharm Des. 2012;18:6090–100.PubMed
73.
Husain S, Abdul Y, Potter DE. Non-Analgesic Effects of Opioids: neuroprotection in the Retina. Curr Pharm Des. 2012;18:6101–8.PubMed
74.
Kromer W. Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev. 1988;40:121–62.PubMed
75.
Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181–7.PubMedPubMedCentral
76.
Collins S, Verma-Gandhu M. The putative role of endogenous and exogenous opiates in inflammatory bowel disease. Gut. 2006;55:756–7.PubMed
77.
Owczarek D, Cibor D, Mach T, Ciesla A, Pierzchala-Koziec K, Salapa K, et al. Met-enkephalins in patients with inflammatory bowel diseases. Adv Med Sci. 2011;56:158–64.PubMed
78.
Al-Khrasani M, Lacko E, Riba P, Kiraly K, Sobor M, Timar J, et al. The central versus peripheral antinociceptive effects of mu-opioid receptor agonists in the new model of rat visceral pain. Brain Res Bull. 2012;87:238–43.PubMed
79.
Xu GY, Winston JH, Chen JD. Electroacupuncture attenuates visceral hyperalgesia and inhibits the enhanced excitability of colon specific sensory neurons in a rat model of irritable bowel syndrome. Neurogastroenterol Motil. 2009;21:1302–e125.
80.
Zadina JE, Hackler L, Ge LJ, Kastin AJ. A potent and selective endogenous agonist for the mu-opiate receptor. Nature. 1997;386:499–502.PubMed
81.
Storr M, Geisler F, Neuhuber WL, Schusdziarra V, Allescher HD. Endomorphin-1 and -2, endogenous ligands for the mu-opioid receptor, inhibit striated and smooth muscle contraction in the rat oesophagus. Neurogastroenterol Motil. 2000;12:441–8.PubMed
82.
Nishiwaki H, Saitoh N, Nishio H, Takeuchi T, Hata F. Relationship between muscarinic autoinhibition and the inhibitory effect of morphine on acetylcholine release from myenteric plexus of guinea pig ileum. Jpn J Pharmacol. 1998;77:271–8.PubMed
83.
Nishiwaki H, Saitoh N, Nishio H, Takeuchi T, Hata F. Inhibitory effect of endomorphin-1 and -2 on acetylcholine release from myenteric plexus of guinea pig ileum. Jpn J Pharmacol. 1998;78:83–6.PubMed
84.
Yu Y, Cui Y, Wang X, Lai LH, Wang CL, Fan YZ, et al. In vitro characterization of the effects of endomorphin 1 and 2, endogenous ligands for mu-opioid receptors, on mouse colonic motility. Biochem Pharmacol. 2007;73:1384–93.PubMed
85.
Azuma Y, Ohura K. Endomorphin-2 modulates productions of TNF-alpha, IL-1beta, IL-10, and IL-12, and alters functions related to innate immune of macrophages. Inflammation. 2002;26:223–32.PubMed
86.
Janecka A, Perlikowska R, Gach K, Wyrebska A, Fichna J. Development of opioid peptide analogs for pain relief. Curr Pharm Des. 2010;16:1126–35.PubMed
87.
Varamini P, Mansfeld FM, Blanchfield JT, Wyse BD, Smith MT, Toth I. Synthesis and biological evaluation of an orally active glycosylated endomorphin-1. J Med Chem. 2012;55:5859–67.PubMed
88.
Kaneko K, Iwasaki M, Yoshikawa M, Ohinata K. Orally administered soymorphins, soy-derived opioid peptides, suppress feeding and intestinal transit via gut mu(1)-receptor coupled to 5-HT(1A), D(2), and GABA(B) systems. Am J Physiol Gastrointest Liver Physiol. 2010;299:G799–805.PubMed
89.
Chiba H, Tani F, Yoshikawa M. Opioid antagonist peptides derived from kappa-casein. J Dairy Res. 1989;56:363–6.PubMed
90.
Patten GS, Head RJ, Abeywardena MY. Effects of casoxin 4 on morphine inhibition of small animal intestinal contractility and gut transit in the mouse. Clin Exp Gastroenterol. 2011;4:23–31.PubMedPubMedCentral
91.
Stefano GB, Ptacek R, Kuzelova H, Kream RM. Endogenous morphine: up-to-date review 2011. Folia Biol. 2012;58:49–56.
92.
Netzer P, Sendensky A, Wissmeyer MP, Baumeler S, Batista C, Scheurer U, et al. The effect of naloxone-3-glucuronide on colonic transit time in healthy men after acute morphine administration: a placebo-controlled double-blinded crossover preclinical volunteer study. Aliment Pharmacol Ther. 2008;28:1334–41.PubMed
93.
Reber P, Brenneisen R, Flogerzi B, Batista C, Netzer P, Scheurer U. Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine. Dig Dis Sci. 2007;52:502–7.PubMed
94.
Ross GR, Gabra BH, Dewey WL, Akbarali HI. Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther. 2008;327:561–72.PubMedPubMedCentral
95.
Aquilante CL, Letrent SP, Pollack GM, Brouwer KL. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 2000;66:L47–51.
96.
King M, Su W, Chang A, Zuckerman A, Pasternak GW. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci. 2001;4:268–74.PubMed
97.
Yousif S, Saubamea B, Cisternino S, Marie-Claire C, Dauchy S, Scherrmann JM, et al. Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein. J Neurochem. 2008;107:647–57.PubMed
98.
Anastassopoulos KP, Chow W, Tapia CI, Baik R, Ackerman SJ, Biondi D, et al. Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. J Manag Care Pharm. 2012;18:615–26.PubMed
99.
Peng X, Cebra JJ, Adler MW, Meissler JJ Jr, Cowan A, Feng P, et al. Morphine inhibits mucosal antibody responses and TGF-beta mRNA in gut-associated lymphoid tissue following oral cholera toxin in mice. J Immunol. 2001;167:3677–81.PubMed
100.
Breslow JM, Feng P, Meissler JJ, Pintar JE, Gaughan J, Adler MW, et al. Potentiating effect of morphine on oral Salmonella enterica serovar Typhimurium infection is mu-opioid receptor-dependent. Microb Pathog. 2010;49:330–5.PubMedPubMedCentral
101.
Feng P, Rahim RT, Cowan A, Liu-Chen LY, Peng X, Gaughan J, et al. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit. Eur J Pharmacol. 2006;534:250–7.PubMed
102.
Babrowski T, Holbrook C, Moss J, Gottlieb L, Valuckaite V, Zaborin A, et al. Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann Surg. 2012;255:386–93.PubMedPubMedCentral
103.
Glattard E, Welters ID, Lavaux T, Muller AH, Laux A, Zhang D, et al. Endogenous morphine levels are increased in sepsis: a partial implication of neutrophils. PLoS ONE. 2010;5:e8791.PubMedPubMedCentral
104.
Capasso R, Borrelli F, Capasso F, Siebert DJ, Stewart DJ, Zjawiony JK, et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil. 2006;18:69–75.PubMed
105.
Fichna J, Schicho R, Andrews CN, Bashashati M, Klompus M, McKay DM, et al. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil. 2009;21:1326-e128.
106.
Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, Zjawiony JK, et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol. 2008;155:681–9.PubMed
107.
Fichna J, Dicay M, Hirota SA, Traboulsi D, Macdonald JA, Janecka A, et al. Differential effects of salvinorin A on endotoxin-induced hypermotility and neurogenic ion transport in mouse ileum. Neurogastroenterol Motil. 2011;23:583-e212.
108.
Fichna J, Dicay M, Lewellyn K, Janecka A, Zjawiony JK, MacNaughton WK, et al. Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors. Inflamm Bowel Dis. 2012;18:1137–45.PubMed
109.
Fichna J, Schicho R, Janecka A, Zjawiony JK, Storr M. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect. 2009;22:383–92.PubMed
110.
Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25:442–53.PubMed
111.
Chen W, Chung HH, Cheng JT. Opiate-induced constipation related to activation of small intestine opioid mu2-receptors. World J Gastroenterol. 2012;18:1391–6.PubMed
112.
Kumar R, Reeta KH, Ray SB. Antinociceptive effect of intrathecal loperamide: role of mu-opioid receptor and calcium channels. Eur J Pharmacol. 2012;696:77–82.PubMed
113.
Primi MP, Bueno L, Baumer P, Berard H, Lecomte JM. Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther. 1999;13:3–7.PubMed
114.
Duncker SC, Philippe D, Martin-Paschoud C, Moser M, Mercenier A, Nutten S. Nigella sativa (Black Cumin) seed extract alleviates symptoms of allergic diarrhea in mice, involving opioid receptors. PLoS One. 2012;7:e39841.PubMedPubMedCentral
115.
Isik F, Tunali AT, Yarat A, Genc Z, Pisiriciler R, Caliskan-Ak E, et al. Protective effects of black cumin (Nigella sativa) oil on TNBS-induced experimental colitis in rats. Dig Dis Sci. 2011;56:721–30.PubMed
116.
Boskabady MH, Mohsenpoor N, Takaloo L. Antiasthmatic effect of Nigella sativa in airways of asthmatic patients. Phytomedicine. 2010;17:707–13.PubMed
117.
Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, et al. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 2010;62:938–46.PubMed
118.
Hirata T, Keto Y, Nakata M, Takeuchi A, Funatsu T, Akuzawa S, et al. Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer. Neurogastroenterol Motil. 2008;20:557–65.PubMed
119.
McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4:231–56.PubMed
120.
Gwee KA. Irritable bowel syndrome in developing countries–a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17:317–24.PubMed
121.
Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11S–8S.PubMed
122.
Deibert P, Xander C, Blum HE, Becker G. Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Core Evid. 2010;4:247–58.PubMedPubMedCentral
123.
Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review. Adv Ther. 2010;27:714–30.PubMed
124.
Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332–43.PubMed
125.
Jakab RL, Collaco AM, Ameen NA. Lubiprostone targets prostanoid signaling and promotes ion transporter trafficking, mucus exocytosis, and contractility. Dig Dis Sci. 2012;57:2826–45.PubMedPubMedCentral
126.
Norimatsu Y, Moran AR, Macdonald KD. Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)). Biochem Biophys Res Commun. 2012;426:374–9.PubMedPubMedCentral
127.
Ao M, Venkatasubramanian J, Boonkaewwan C, Ganesan N, Syed A, Benya RV, et al. Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci. 2011;56:339–51.PubMed
128.
Sun X, Wang X, Wang GD, Xia Y, Liu S, Qu M, et al. Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. Dig Dis Sci. 2011;56:330–8.PubMed
129.
Fei G, Raehal K, Liu S, Qu MH, Sun X, Wang GD, et al. Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther. 2010;334:333–40.PubMed
130.
Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf. 2012;11:841–50.PubMed
131.
Kalff JC, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents. Gastroenterology. 2000;118:316–27.PubMed
132.
Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. Neurogastroenterol Motil. 2004;16:54–60.PubMed
133.
Beard TL, Leslie JB, Nemeth J. The opioid component of delayed gastrointestinal recovery after bowel resection. J Gastrointest Surg. 2011;15:1259–68.PubMed
134.
Thompson M, Magnuson B. Management of postoperative ileus. Orthopedics. 2012;35:213–7.PubMed
135.
Pfab F, Nowak-Machen M, Napadow V, Fleckenstein J. Alternatives to prokinetics to move the pylorus and colon. Curr Opin Clin Nutr Metab Care. 2012;15:166–73.PubMed
136.
Schmidt J, Stoffels B, Nazir A. haven-Hudkins DL, Bauer AJ. Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus. Neurogastroenterol Motil. 2008;20:689–99.PubMed
137.
Delaney CP, Weese JL, Hyman NH, Bauer J, Techner L, Gabriel K, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum. 2005;48:1114–25.PubMed
138.
Apfel CC, Jalota L. Can central antiemetic effects of opioids counter-balance opioid-induced nausea and vomiting? Acta Anaesthesiol Scand. 2010;54:129–31.PubMed
139.
Marderstein EL, Delaney CP. Management of postoperative ileus: focus on alvimopan. Ther Clin Risk Manag. 2008;4:965–73.PubMedPubMedCentral
140.
Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428–40.PubMed
141.
Paulson DM, Kennedy DT, Donovick RA, Carpenter RL, Cherubini M, Techner L, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—a 21-day treatment-randomized clinical trial. J Pain. 2005;6:184–92.PubMed
142.
Jansen JP, Lorch D, Langan J, Lasko B, Hermanns K, Kleoudis CS, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12:185–93.PubMed
143.
Irving G, Penzes J, Ramjattan B, Cousins M, Rauck R, Spierings EL, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12:175–84.PubMed
144.
Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240:728–34.PubMed
145.
Viscusi ER, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006;20:64–70.PubMed
146.
Buchler MW, Seiler CM, Monson JR, Flamant Y, Thompson-Fawcett MW, Byrne MM, et al. Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther. 2008;28:312–25.PubMed
147.
Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001;345:935–40.PubMed
148.
Ludwig K, Enker WE, Delaney CP, Wolff BG, Du W, Fort JG, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg. 2008;143:1098–105.PubMed
149.
Herzog TJ, Coleman RL, Guerrieri JP Jr, Gabriel K, Du W, Techner L, et al. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol. 2006;195:445–53.PubMed
150.
Ludwig K, Viscusi ER, Wolff BG, Delaney CP, Senagore A, Techner L. Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. World J Surg. 2010;34:2185–90.PubMedPubMedCentral
151.
Itawi EA, Savoie LM, Hanna AJ, Apostolides GY. Alvimopan addition to a standard perioperative recovery pathway. JSLS. 2011;15:492–8.PubMedPubMedCentral
152.
Poston S, Broder MS, Gibbons MM, Maclaren R, Chang E, Vandepol CJ, et al. Impact of alvimopan (entereg) on hospital costs after bowel resection: results from a large inpatient database. P T. 2011;36:209–20.PubMedPubMedCentral
153.
Delaney CP, Craver C, Gibbons MM, Rachfal AW, VandePol CJ, Cook SF, et al. Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection. Ann Surg. 2012;255:731–8.PubMed
154.
Vaughan-Shaw PG, Fecher IC, Harris S, Knight JS. A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery. Dis Colon Rectum. 2012;55:611–20.PubMed
155.
Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011;5:201–11.PubMedPubMedCentral
156.
Wong BS, Rao AS, Camilleri M, Manabe N, McKinzie S, Busciglio I, et al. The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment Pharmacol Ther. 2010;32:884–93.PubMed
157.
Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology. 1997;87:765–70.PubMed
158.
Yuan CS, Foss JF, Osinski J, Toledano A, Roizen MF, Moss J. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther. 1997;61:467–75.PubMed
159.
Michna E, Weil AJ, Duerden M, Schulman S, Wang W, Tzanis E, et al. Efficacy of subcutaneous methylnaltrexone in the treatment of opioid-induced constipation: a responder post hoc analysis. Pain Med. 2011;12:1223–30.PubMed
160.
Iyer SS, Randazzo BP, Tzanis EL, Schulman SL, Zhang H, Wang W, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health. 2011;14:177–83.PubMed
161.
Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12:554–62.PubMed
162.
Yu CS, Chun HK, Stambler N, Carpenito J, Schulman S, Tzanis E, et al. Safety and efficacy of methylnaltrexone in shortening the duration of postoperative ileus following segmental colectomy: results of two randomized, placebo-controlled phase 3 trials. Dis Colon Rectum. 2011;54:570–8.PubMed
163.
Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012;7:67–72.PubMed
164.
Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, et al. Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness. J Pain Symptom Manage. 2009;38:683–90.PubMed
165.
Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7:39–46.PubMed
166.
Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008;35:458–68.
167.
Lipman AG, Karver S, Cooney GA, Stambler N, Israel RJ. Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study. J Pain Palliat Care Pharmacother. 2011;25:136–45.PubMed
168.
Yuan CS, Foss JF, O’connor M, Osinski J, Karrison T, Moss J, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000;283:367–72.PubMed
169.
Garnock-Jones KP, McKeage K. Methylnaltrexone. Drugs. 2010;70:919–28.
170.
Garten L, Degenhardt P, Buhrer C. Resolution of opioid-induced postoperative ileus in a newborn infant after methylnaltrexone. J Pediatr Surg. 2011;46:e13–5.PubMed
171.
Fichna J, Gach K, Perlikowska R, Cravezic A, Bonnet JJ, do-Rego JC, et al. Novel endomorphin analogues with antagonist activity at the mu-opioid receptor in the gastrointestinal tract. Regul Pept. 2010;162:109–14.
172.
Fichna J, Storr MA. Brain-gut interactions in IBS. Front Pharmacol. 2012;3:127.
173.
174.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen V, Hamm LR, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005;22:935–42.PubMed
175.
Wilkins T, Pepitone C, Alex B, Schade RR. Diagnosis and management of IBS in adults. Am Fam Physician. 2012;86:419–26.PubMed
176.
Philpott H, Gibson P, Thien F. Irritable bowel syndrome—an inflammatory disease involving mast cells. Asia Pac Allergy. 2011;1:36–42.PubMedPubMedCentral
177.
Alaradi O, Barkin JS. Irritable bowel syndrome: update on pathogenesis and management. Med Princ Pract. 2002;11:2–17.PubMed
178.
Distrutti E, Mencarelli A, Renga B, Caliendo G, Santagada V, Severino B, et al. A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. Pharmacol Res. 2009;59:319–29.PubMed
179.
Lee N, Wald A. Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation. Core Evid. 2012;7:39–47.PubMedPubMedCentral
180.
Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clin Exp Gastroenterol. 2012;5:69–100.PubMedPubMedCentral
181.
Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:918–32.PubMed
182.
Philippe D, Dubuquoy L, Groux H, Brun V, Chuoi-Mariot MT, Gaveriaux-Ruff C, et al. Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. J Clin Invest. 2003;111:1329–38.PubMedPubMedCentral
183.
Srinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol. 2012;5:339–57.PubMedPubMedCentral
184.
Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schafer M, Loeffler JP, et al. Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest. 1997;100:142–8.PubMedPubMedCentral
185.
Tomassini N, Renaud FL, Roy S, Loh HH. Mu and delta receptors mediate morphine effects on phagocytosis by murine peritoneal macrophages. J Neuroimmunol. 2003;136:9–16.PubMed
186.
Philippe D, Chakass D, Thuru X, Zerbib P, Tsicopoulos A, Geboes K, et al. Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut. 2006;55:815–23.PubMed
187.
Goldsmith JR, Uronis JM, Jobin C. Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling. Am J Pathol. 2011;179:673–83.PubMed
188.
Matters GL, Harms JF, McGovern C, Fitzpatrick L, Parikh A, Nilo N, et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008;5:179–87.PubMed
189.
Jan WC, Chen CH, Hsu K, Tsai PS, Huang CJ. L-type calcium channels and mu-opioid receptors are involved in mediating the anti-inflammatory effects of naloxone. J Surg Res. 2011;167:e263–72.PubMed
190.
Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011;56:2088–97.PubMedPubMedCentral
191.
Hilburger ME, Adler MW, Truant AL, Meissler JJ Jr, Satishchandran V, Rogers TJ, et al. Morphine induces sepsis in mice. J Infect Dis. 1997;176:183–8.PubMed
192.
Topcu I, Ekici NZ, Isik R, Sakarya M. The effects of tramadol and fentanyl on gastrointestinal motility in septic rats. Anesth Analg. 2006;102:876–81.PubMed
193.
194.
Tang CW, Feng WM, Du HM, Bao Y, Zhu M. Delayed administration of D-Ala2-D-Leu5-enkephalin, a delta-opioid receptor agonist, improves survival in a rat model of sepsis. Tohoku J Exp Med. 2011;224:69–76.PubMed
195.
Goins WF, Cohen JB, Glorioso JC. Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol Dis. 2012;48:255–70.PubMedPubMedCentral
196.
Fink DJ, Wechuck J, Mata M, Glorioso JC, Goss J, Krisky D, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70:207–12.PubMedPubMedCentral
Metadata
Title
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives
Authors
Marta Sobczak
Maciej Sałaga
Martin A. Storr
Jakub Fichna
Publication date
01-01-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 1/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-013-0753-x

Other articles of this Issue 1/2014

Journal of Gastroenterology 1/2014 Go to the issue

Review

Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor

Rapid Communication

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies

Original Article—Liver, Pancreas, and Biliary Tract

Photodynamic therapy for human hepatoma-cell–line tumors utilizing biliary excretion properties of indocyanine green

Original Article—Alimentary Tract

C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma

Original Article—Alimentary Tract

Evaluation of diagnostic criteria for Crohn’s disease in Japan

Original Article—Liver, Pancreas, and Biliary Tract

Impact of hospital volume on outcomes in acute pancreatitis: a study using a nationwide administrative database
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits